Source: Rossiyskaya Gazeta, special project ST. PETERSBURG INTERNATIONAL ECONOMIC FORUM
Despite the challenges posed by economic sanctions, international pharmaceutical companies remain active in our country. Most of them operate in the same manner as before, while a small number have adjusted their business models. However, they continue to provide medicines and support initiatives for patients, as stated by Larisa Matveeva, the Executive Director of the Association of International Pharmaceutical Manufacturers (AIPM), in an interview with RG at SPIEF 2024. The sanctions have undoubtedly impacted the entire market. The disruption of logistics, difficulties in sourcing raw materials, and import and export restrictions are issues that affect everyone. However, the members of our association have successfully adapted to these challenges. They are actively engaged in their operations and eagerly anticipate a constructive dialogue and collaboration with the government. It is crucial to preserve these relationships and to continue to work together to find common ground and the best possible solutions, as all pharmaceutical companies strive to serve the needs of patients.
Nowadays, we frequently discuss the importance of innovative medications for patients. Innovation is a form of intellectual property. To ensure the availability of these medicines, to foster the development and dissemination of our own pharmaceutical innovations, it is crucial to safeguard them, so that pharmaceutical companies can remain confident in their business prospects. The head of the AIPM emphasizes that the principles and regulations governing the protection of intellectual property must be transparent. Compulsory licensing is indeed a valuable instrument with clear public objectives, but we must establish clear criteria for its implementation. Companies must be able to deliver and fulfill their obligations without uncertainty or insecurity regarding intellectual property, as Ms. Matveeva believes.
Despite the challenges posed by economic sanctions, international pharmaceutical companies remain active in our country. Most of them operate in the same manner as before, while a small number have adjusted their business models. However, they continue to provide medicines and support initiatives for patients, as stated by Larisa Matveeva, the Executive Director of the Association of International Pharmaceutical Manufacturers (AIPM), in an interview with RG at SPIEF 2024. The sanctions have undoubtedly impacted the entire market. The disruption of logistics, difficulties in sourcing raw materials, and import and export restrictions are issues that affect everyone. However, the members of our association have successfully adapted to these challenges. They are actively engaged in their operations and eagerly anticipate a constructive dialogue and collaboration with the government. It is crucial to preserve these relationships and to continue to work together to find common ground and the best possible solutions, as all pharmaceutical companies strive to serve the needs of patients.
Nowadays, we frequently discuss the importance of innovative medications for patients. Innovation is a form of intellectual property. To ensure the availability of these medicines, to foster the development and dissemination of our own pharmaceutical innovations, it is crucial to safeguard them, so that pharmaceutical companies can remain confident in their business prospects. The head of the AIPM emphasizes that the principles and regulations governing the protection of intellectual property must be transparent. Compulsory licensing is indeed a valuable instrument with clear public objectives, but we must establish clear criteria for its implementation. Companies must be able to deliver and fulfill their obligations without uncertainty or insecurity regarding intellectual property, as Ms. Matveeva believes.